E. Dalmau

1.1k total citations
27 papers, 695 citations indexed

About

E. Dalmau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, E. Dalmau has authored 27 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in E. Dalmau's work include Breast Cancer Treatment Studies (7 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (6 papers). E. Dalmau is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (6 papers). E. Dalmau collaborates with scholars based in Spain, United States and Mexico. E. Dalmau's co-authors include C. Casas, José Luis González Montesinos, Marina Lotti, P. Lianes, Margarita Majem, Jordi Remón, Noemı́ Reguart, Teresa Morán, Diego Márquez-Medina and Miguel Ángel Seguí and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

E. Dalmau

26 papers receiving 650 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Dalmau Spain 10 346 273 251 124 95 27 695
Anbok Lee South Korea 13 232 0.7× 165 0.6× 192 0.8× 128 1.0× 64 0.7× 42 694
Jai Balkissoon United States 14 314 0.9× 112 0.4× 252 1.0× 114 0.9× 52 0.5× 20 757
Hongyang Lu China 18 242 0.7× 375 1.4× 453 1.8× 106 0.9× 45 0.5× 84 888
Zhen Zong China 15 358 1.0× 210 0.8× 208 0.8× 284 2.3× 29 0.3× 74 799
Jie Shen China 15 252 0.7× 203 0.7× 443 1.8× 154 1.2× 96 1.0× 65 902
Xuelian Chen China 12 218 0.6× 209 0.8× 462 1.8× 163 1.3× 43 0.5× 36 779
Yantao Tian China 10 287 0.8× 134 0.5× 319 1.3× 204 1.6× 44 0.5× 26 701
Hong-Yun Zhao China 13 321 0.9× 220 0.8× 394 1.6× 82 0.7× 30 0.3× 21 775
Putao Cen United States 15 226 0.7× 251 0.9× 360 1.4× 149 1.2× 28 0.3× 38 759

Countries citing papers authored by E. Dalmau

Since Specialization
Citations

This map shows the geographic impact of E. Dalmau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Dalmau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Dalmau more than expected).

Fields of papers citing papers by E. Dalmau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Dalmau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Dalmau. The network helps show where E. Dalmau may publish in the future.

Co-authorship network of co-authors of E. Dalmau

This figure shows the co-authorship network connecting the top 25 collaborators of E. Dalmau. A scholar is included among the top collaborators of E. Dalmau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Dalmau. E. Dalmau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aix, Santiago Ponce, Enric Carcereny, Joaquim Bosch‐Barrera, et al.. (2021). 160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I. Annals of Oncology. 32. S1450–S1450. 5 indexed citations
2.
González-Santiago, Santiago, Cristina Saura, Eva Ciruelos, et al.. (2020). Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study). Breast Cancer Research and Treatment. 184(2). 469–479. 15 indexed citations
3.
Álvarez, Isabel, Susana Bezares, E. Dalmau, et al.. (2020). Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer. Clinical & Translational Oncology. 22(8). 1364–1377.
4.
Mayoral, María, Eva Castañer, Xavier Gallardo, et al.. (2019). Pseudoprogresión tumoral en el tratamiento inmunoterápico con nivolumab en el cáncer de pulmón. Radiología. 61(6). 498–505. 3 indexed citations
5.
Ayala, Francisco, Raquel Andrés, José Á. García-Sáenz, et al.. (2018). SEOM clinical guidelines in early stage breast cancer (2018). Clinical & Translational Oncology. 21(1). 18–30. 47 indexed citations
6.
7.
Sentís, Melcior, et al.. (2016). Carcinoma de mama triple negativo. Heterogeneidad inmunofenotípica y en el comportamiento farmacocinético. Radiología. 58(1). 55–63. 4 indexed citations
8.
Bonet, Marta, Pere Godoy, M. Algara, et al.. (2014). Are breast cancer patients treated with radiotherapy younger now than ten years ago?. Reports of Practical Oncology & Radiotherapy. 20(1). 22–26. 1 indexed citations
9.
Dalmau, E., et al.. (2014). Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. The Breast. 23(6). 710–720. 31 indexed citations
10.
Sánchez‐Rovira, Pedro, Miguel Ángel Seguí, Antonio Llombart‐Cussac, et al.. (2013). Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. Clinical & Translational Oncology. 15(10). 810–817. 9 indexed citations
11.
Sánchez, José Juan González, et al.. (2013). SBRT in the treatment of NSCLC stages I–II. Reports of Practical Oncology & Radiotherapy. 18. S268–S268. 1 indexed citations
12.
Remón, Jordi, Teresa Morán, Margarita Majem, et al.. (2013). Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins. Cancer Treatment Reviews. 40(1). 93–101. 106 indexed citations
13.
Bonfill, Teresa, et al.. (2010). Haemolytic uraemic syndrome associated with gemcitabine. Clinical & Translational Oncology. 12(5). 381–383. 1 indexed citations
14.
Dalmau, E., et al.. (2010). Efficacy and safety of intrapericardial bleomycin for malignant pericardial effusion.. Journal of Clinical Oncology. 28(15_suppl). e19687–e19687. 3 indexed citations
15.
Dalmau, E., et al.. (2008). Rectovaginal Septum Metastasis: An Unusual Presentation of Fallopian Tube Carcinoma. American Journal of Clinical Oncology. 31(4). 405–406. 2 indexed citations
16.
Seguí, Miguel Ángel, Xavier Andreu, E. Dalmau, et al.. (2007). Analysis of the Pathologic Response to Primary Chemotherapy in Patients with Locally Advanced Breast Cancer Grouped According to Estrogen Receptor, Progesterone Receptor, and HER2 Status. Clinical Breast Cancer. 7(7). 559–564. 29 indexed citations
17.
Pericay, Carles, et al.. (2007). Epidermal growth factor receptor (EGFR) as a prognostic factor over 10 years in non-metastasic colon carcinoma (NMCC). Journal of Clinical Oncology. 25(18_suppl). 21062–21062. 1 indexed citations
18.
Darnell, Anna, E. Dalmau, Carles Pericay, et al.. (2006). Gastrointestinal stromal tumors. Abdominal Imaging. 31(4). 387–399. 34 indexed citations
19.
Dalmau, E., et al.. (2006). Gastrointestinal stromal tumors: experience in 49 patients. Clinical & Translational Oncology. 8(8). 594–598. 5 indexed citations
20.
Dalmau, E., Àngels Arcusa, Carles Pericay, et al.. (2006). Analysis of the pathological response to primary chemotherapy in patients with locally advanced breast cancer (LABC) grouped according to ER, PR and HER2 status. Journal of Clinical Oncology. 24(18_suppl). 626–626. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anbok Lee Breakdown of academic impact, for papers by Jai Balkissoon Breakdown of academic impact, for papers by Hongyang Lu Breakdown of academic impact, for papers by Zhen Zong Breakdown of academic impact, for papers by Jie Shen Breakdown of academic impact, for papers by Xuelian Chen Breakdown of academic impact, for papers by Yantao Tian Breakdown of academic impact, for papers by Hong-Yun Zhao Breakdown of academic impact, for papers by Putao Cen
Rankless by CCL
2026